Synonyms that are in the dictionary are marked in green. Synonyms that are not in the dictionary are marked in red.
Antonyms that are in the dictionary are marked in green. Antonyms that are not in the dictionary are marked in red.
Amjevita represents the first biosimilar to the blockbuster drug Humira, kicking off what will likely be a firestorm of clones.
Source: https://investorplace.com/2023/01/amgen-layoffs-2023-what-to-know-about-the-latest-amgn-job-cuts/
He also believes the deal will help drive adjusted-earnings growth over the next five years, which is crucial considering how Humira biosimilars will likely create a drag on earnings for several years.
Source: https://medcitynews.com/2023/11/abbvie-adc-cancer-pharma/
Humira has become the best-selling drug in history, with about in all-time global sales.
Source: https://fortune.com/2023/04/13/horizon-therapeutics-drug-marketing-amgen-acquisition/
Its sales peaked last year at $21.2 billion, but its losses could be more than offset by a pair of more recently launched drugs aimed at the same patient groups as Humira.
Source: https://moneymorning.com/investing/abbvies-blockbuster-is-falling-fast-time-to-sell/
Management also expects to this year a biosimilar for arthritis treatment, Humira, pending U.S. regulatory approval, to boost revenue.
Management believes these two drugs have the ability to be blockbusters, and they expect the combination of both to surpass peak Humira sales, which is very encouraging for investors.
Naturally, if there is a more effective and safe drug than Humira available for the same indication, then physicians are likely to prescribe it over Humira, or a Humira biosimilar.
Naturally, if there is a more effective and safe drug than Humira available for the same indication, then physicians are likely to prescribe it over Humira, or a Humira biosimilar.
Naturally, if there is a more effective and safe drug than Humira available for the same indication, then physicians are likely to prescribe it over Humira, or a Humira biosimilar.
The company's lead asset - all-time best selling immunology drug Humira - finally loses patent protection this year and sales will enter a period of terminal decline.